Chimerix (CMRX) Stock Analysis

What Chimerix does

Chimerix, Inc. operates as a biopharmaceutical company, committed to advancing therapeutic solutions that improve the lives of individuals grappling with severe medical conditions. Its sole approved medicine is TEMBEXA (brincidofovir), a lipid conjugate designed to combat smallpox by inhibiting viral DNA synthesis, positioned as a critical medical countermeasure. Beyond its commercial offering, Chimerix boasts a robust clinical-stage pipeline: ONC201 targets recurrent diffuse midline glioma in patients whose tumors possess the H3 K27M mutation. ONC206, an imipridone, is a Phase I candidate for solid tumors, functioning as both a Dopamine Receptor D2 (DRD2) antagonist and a caseinolytic protease P (ClpP) agonist. Notably, it exhibits superior non-competitive antagonism of DRD2 compared to ONC201. ONC212, another imipridone, acts as an agonist for the orphan G protein-coupled receptor (GPCR) tumor suppressor GPR132 and ClpP. This compound is being explored for a range of solid tumors and blood cancers, including pancreatic cancer and leukemias. dociparstat sodium (DSTAT) aims to overcome chemotherapy resistance in acute myeloid leukemia (AML) by inhibiting crucial proteins found in leukemic blasts and stem cells. Chimerix has also forged strategic partnerships, including licensing agreements with: The Biomedical Advanced Research and Development Authority (BARDA) for brincidofovir's smallpox treatment development. Cantex Pharmaceuticals, Inc. for the development and commercialization of a glycosaminoglycan compound. SymBio Pharmaceuticals for the development, manufacturing, and commercialization of BCV (brincidofovir) across multiple human indications. Established in 2000, Chimerix, Inc. maintains its headquarters in Durham, North Carolina.

Key metrics

ETFs linked to CMRX

Broad-market and Healthcare sector ETFs an investor holding Chimerix is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how CMRX fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Chimerix?

Chimerix trades under the ticker CMRX on NASDAQ.

Which exchange is CMRX listed on?

CMRX is listed on NASDAQ.

What sector does Chimerix operate in?

Chimerix is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze CMRX in a portfolio?

PortView shows CMRX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.